Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06203314

Epstein-Barr Virus and Cancer Risks

The goal of this prospective cohort study is to investigate the associations between Epstein-Barr Virus (EBV) antibody levels and the risk of overall and site-specific cancer types in Southern China. The main questions it aims to answer are:

Question 1: In addition to the established EBV-associated cancer types, such as lymphomas, nasopharyngeal carcinoma, and stomach cancer, whether EBV is associated with other cancer types? Question 2: What's the cancer burden attributed to EBV in Southern China?

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Cancer Neoplasms

Age range

30 year–69 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Zhongshan People's Hospital, Zhongshan, Guangdong, China

Loading trial locations.

About this study

Growing molecular evidence suggests the involvement of EBV in various cancers, however, comprehensive epidemiological evidence is still lacking. In this study, researchers conducted a population-based prospective cohort study to investigate the associations between EBV antibodies and the risk of overall and site-specific cancer types in Southern China. All the participants underwent EBV antibody tests at enrollment and were subsequently followed up annually for cancer incidence, vital status, and immigration status. The primary objective of this study was to provide prospective evidence for the role of EBV in multiple cancers, shedding light on the etiology of a broad range of common EBV-associated cancers.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject residents in Zhongshan or Wuzhou City;
  • Subject has no medical record of prevalent cancer;
  • Subject has psychical condition and well consciousness, and willingness to accept and cooperate with the study's follow-up procedures.

Exclusion criteria

  • Subject has heavy cardiovascular, liver, or kidney disease;
  • Subject has prevalent cancer.

Treatment and study plan

Diagnostic test: EBV antibody tests

Other

Participants underwent several EBV antibody tests, including VCA-IgA, EBNA1-IgA, etc.

Primary outcomes

  1. Cancer incidence

    Time frame: 10 years

    The primary outcome of the study was the diagnosis of any type of cancer. The cancer type for each participant was defined as their initial and primary cancer diagnosis.

Secondary outcomes

  1. All-cause mortality

    Time frame: 10 years

    The participants were followed up annually for cancer incidence, vital status and immigration status through the Cancer Registry, Death Registry, and Population Registry of local regions.

Study contacts

Contact information is provided by the study sponsor or research team.

Wei-Hua Jia

CONTACT

[email protected]

86+020-87342327

Yong-Qiao He

CONTACT

[email protected]

86+020-87342410

Sponsors and collaborators

Lead sponsor

Sun Yat-sen University

Other

Collaborators

  • Wuzhou Red Cross Hospital
  • Zhongshan People's Hospital, Guangdong, China

Registry information

Official study title

Prospective Cohort Study on Epstein-Barr Virus Antibody and Cancer Risks

Acronym: EBVCR

Important dates

Study start
2008
Primary completion
2024
Study completion
2030
First posted
Jan 12, 2024
Registry last updated
Jan 12, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.